|| List of recent Casein-related patents
|Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (ibd)|
A nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease is disclosed. The nutritional composition comprises casein protein, vitamin k in a ratio of vitamin k1:vitamin k2 being between 3:1 to 1:3 and the vitamin k providing between 3.5-20 μg/100 kcal of the nutritional composition, vitamin d and alpha-linolenic acid.
|Casein products and c02 reversible acidification methods used for their production|
The invention provides methods for improving at least one physicochemical property of a product comprising casein micelles, the method comprising applying carbon dioxide to an aqueous product comprising casein micelles to reduce the ph of the product; increasing the ph of the product; and collecting the product comprising casein micelles, in which at least some of the casein micelles of the product are modified in structure by one or more of steps a) and b) compared to naturally occurring casein micelles thereby improving at least one physicochemical property of the product comprising casein micelles. The method reduces viscosity and improves mouth feel of reconstituted product, reduces rehydration time for dried product, improves cheese manufacturing by reducing rennetting or clotting time in cheese manufacture or reducing the amount of rennet required in cheese manufacture..
Murray Goulburn Co-operative Co. Limited
|Method for producing a protein and lipid comprising composition with reduced digestive coagulation|
The present invention relates to a process of producing a composition comprising at least two different proteins, of which at least one is a casein and at least one is an anti-coagulating protein, comprising the steps of: a) heat-sterilising a first liquid component which comprises said casein in an amount of at least 85 wt % of the total protein content of the first component, b) heat-sterilising a second liquid component comprising said anti-coagulating protein, and c) mixing said first component with said second component to obtain a mixture thereof. The obtained mixture is useful as a food constituent having reduced coagulation in the upper gastro-intestinal tract, more in particular in the stomach..
|High energy liquid enteral nutritional composition|
High energy and high protein liquid nutrition enteral compositions are provided that contain micellar casein and caseinate, an optionally a small amount of whey.. .
|Milk products with increased water binding|
The present invention relates to a casein concentrate wherein the milk protein comprises not more than 10% serum protein, and wherein the casein micelles have an average size of less than 175 nm in diameter; and wherein the concentrate has a ph below 6,7. Treating milk so as to shift the equilibrium out of the casein micelles and towards the serum phase modifies the micelles so as to allow increased water binding by the casein concentrate.
Arla Foods Amba
|Novel casein protein product|
The present invention relates to a process for producing a casein protein product comprising the steps of:—providing a casein concentrate starting material,—heat-treating the material,—cooling the heat-treated material,—subjecting the cooled material to a treatment with a crosslinking enzyme,—optionally subjecting the cooled material to a treatment with a coagulant and—processing the material into the casein protein product/allowing the casein protein product to form.. .
|Multilayer mucoadhering patch with a nonadhering layer comprising casein|
A multilayer, mucoadhering patch, comprising a first, exposed layer of adhesive material including a polymer that is capable of adhering to a wet mucous surface in a human or other animal; and a second, exposed layer of nonadhesive material comprising casein.. .
|Method for nanocapsulation of hydrophobic compounds and compositions thereof|
Nanoencapsulation of hydrophobic compounds using native casein micelles by means of ph changes and ultrasonication.. .
Tarbiat Modaress University
The invention relates to a polypeptide having chymosin activity which: a. Is capable of hydrolysing bovine alpha s1-casein at position f23f24 so as to form αs1-i cn (f24-199) more rapidly than camel chymosin; and b.
Dsm Ip Assets B.v.
|Novel substituted pyrazolo-piperazines as casein kinase 1 d/e inhibitors|
And pharmaceutically acceptable salts thereof. The compounds of formula (i) inhibit protein kinase activity thereby making them useful as anticancer agents..
Polymeric compositions comprising polyisoprene
A glove, including a polymeric, elastomeric, or latex composition, having a water-based emulsion of a polyisoprene polymer; a first accelerator comprising at least one of a thiourea, a benzothiazole sulphenamide, a thiazole, or a dialkyl dithiocarbamate, or combinations thereof, a second accelerator comprising a thiuram or a xanthogen, or a combination thereof, at least one anti-oxidant, at least one vulcanizing agent; and an activator, wherein a total amount of the first accelerator and the second accelerator ranges from 0.2 to 2.5 phr of the polymeric, elastomeric, or latex composition and the polymeric, elastomeric, or latex composition is substantially free of diphenyl guanidine and/or casein.. .
Immunochromatography detection method
The present invention provides an immunochromatography detection method capable of suppressing non-specific reactions. The present invention relates to an immunochromatography detection method including: a step of adding an analyte dilution solution containing an analyte to a chromatography medium; a step of recognizing a detection target by a labeling substance modified with gold nanoparticles, which is dry-retained at a labeling substance retaining part; a step of developing a composite of the labeling substance and the detection target as a mobile phase; and a step of detecting the detection target in the developed mobile phase at a judgment part, wherein the labeling substance is protected with a polyalkylene glycol having one or more mercapto groups and/or a derivative thereof and then dry-retained together with arginine and casein at the labeling substance retaining part..
Tanaka Kikinzoku Kogyo K.k.
Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs
This invention is related to a pharmaceutical combination that contains a casein kinase 2 (ck2) peptide inhibitor (termed p15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin c, imatinib, iressa, velcade (bortezomib), cytarabine (ara c), fludarabine and mitroxantrone.
Centro De Ingenieria Genetica Y Biotecnologia
Bioactive complex compositions and methods of use thereof
A bioactive complex composition having enhanced oxidative stability, emulsion stability, mineral rich transparent beverages and a wide range of functional health benefits. The composition may include as a base composition individual ingredients or a synergistic blend of mineral salts, omega-3 rich oils, phospholipids, chitosan, and alpha-casein, beta-casein, kappa-casein or protein fragments, glycopeptides, phosphopeptides.
Texas A&m University System
Methods for treating heat stress and related compositions
Methods of treating, reducing, and/or preventing heat stress are provided. For example, provided is a method of treating or preventing heat stress in a subject comprising selecting a subject in need of heat stress treatment or prevention and administering an effective amount of one or more of astaxanthin and milk casein hydrolysate, or a derivative thereof to the subject.
Method for inhibiting aggregate formation during protein hydrolysis
Disclosed is for inhibiting gel formation during, or resulting from, hydrolysis of protein compositions comprising casein.. .
Glanbia Nutritionals (ireland) Plc
Methods for screening inhibitors of tau phosphorylation by casein kinase i
Methods of screening for candidate compounds capable of inhibiting activity of fyn in phosphorylating tau protein at y394 or binding to fyn to inhibit interaction with tau protein at y394, including determining whether, and optionally the extent, the candidate compounds have these capabilities under conditions where fyn has these capabilities in the absence of the candidate compound. Methods of screening for substances capable of promoting dephosphorylation of tau protein by a phosphatase at a site of tau protein including contacting a candidate substance, the tau protein and a phosphatase capable of dephosphorylating the tau protein under conditions where the phosphatase is capable of dephosphorylating the site in absence of the candidate substance, where the kinase is fyn; determining whether, and optionally the extent, the candidate substance promotes dephosphorylation of the tau protein at the site; and selecting the candidate substance which promotes dephosphorylation of the tau protein the sites..
King's College London
The invention relates to peptides including dede(ssd)ndeg indicated by seq no. 1, rrrdede(ssd)ndeg indicated by seq no.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Energy-rich liquid nutritional composition having improved organoleptic properties
The object of the present invention is to provide a liquid enteral composition for providing nutrition, either as a supplement, or as a complete nutrition, comprising a high protein content, in particular micellar casein as major protein source, in a small volume of liquid, in particular 6 to 20 g protein per 100 ml of the liquid composition, the composition further comprising lactic acid and having a ph in the range of 6 to 8. It is also an object of the invention to provide an improved manufacturing process for such liquid enteral compositions..
Kluyveromyces lactis yeast strain and methods for the production of sugars, ethanol, beta-galactosidase and biomass
The present invention is a kluyveromyces lactis yeast strain comprising the sequence identified by seq id no: 1, and methods for the production of sugars (glucose and galactose), ethanol, β-galactosidase and biomass, in which said kluyveromyces lactis yeast strain is cultured in the presence of a lactose-containing medium. The lactose-containing medium may be milk, whey, whey resulting from the preparation of butter, whey resulting after casein precipitation, milk permeate, whey permeate, acid whey and ypl culture medium..
Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs
This invention is related to a pharmaceutical combination that contains a casein kinase 2 (ck2) peptide inhibitor (termed p15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin c, imatinib, iressa and velcade (bortezomib).
Centro De Ingenieria Genetica Y Biotecnologia
Use of fermented milk product for skin treatment
The use of a fermented milk product comprising non-hydrolysed whey proteins which is substantially free of casein proteins for the purpose of improving skin firmness, by structuring collagen without promoting collagen synthesis, when topically applied to skin is provided.. .
Quest International Services B.v.
Uses of casein compositions
casein compositions for increasing the rate of gastric emptying following ingestion of the composition, increasing the digestibility of a protein composition, or increasing the rate of delivery of amino acids to the blood, or for increasing the blood serum concentration of free leucine in a subject, preferably to substantially the same level as whey protein, the casein being about 10 to about 100% calcium depleted, having a degree of hydrolysis less than about 1% and having an unmodified phosphorylation pattern.. .
Fonterra Co-operative Group Limited
Stabilized concentrated liquid human milk fortifier
Disclosed are shelf-stable concentrated liquid human milk fortifiers including extensively hydrolyzed casein. The long term shelf stable, concentrated liquid human milk fortifiers include octenyl succinic acid (osa) modified waxy potato starch as a stabilizer..
Concentrated low water activity liquid human milk fortifier including extensively hydrolyzed protein
Disclosed are concentrated liquid human milk fortifiers including extensively hydrolyzed casein, and optionally a probiotic. The concentrated liquid human milk fortifier has a low water activity and a low ph, thereby reducing microbial growth in the fortifier..
Composition to overcome inhibitors in pcr and growth cultures
Provided herein are compositions and methods for improving amplification or detection of a target nucleic acid in a sample containing pcr inhibitors, such as polyphenols. One aspect provides an enhancer composition including casein or polyvinylpyrrolidone, or a modified polymer thereof.
Method for producing fructosyl valyl histidine oxidase preparation
A method for producing a fvho preparation comprising a step of allowing at least one member selected from phosphoric acid, casein peptone, d-glucosamine hydrochloride, melibiose, sorbose, lactose, fructose, melezitose, glucono-1,5-lactone, and ribitol; and a method for producing a dried fvho preparation, comprising a step of allowing bicine to coexist.. .
Nutritional composition comprising whey and hydrolyzed casein and uses thereof
The present disclosure provides a nutritional composition, such as a preterm infant formula that includes a protein source comprising whey protein and hydrolyzed casein protein. The whey protein to hydrolyzed casein ratio may be from about 90:10 to about 50:50 by weight.
Protein fortified yogurts and methods of making
Methods of making protein-fortified yogurt products are described. The methods may include mixing a casein-containing ingredient with starting milk to make a yogurt milk, where the casein-containing ingredient has a casein-to-whey protein ratio of 82:18 or greater.
Reduced calorie infant formulas containing specific whey to casein ratios
The present disclosure is directed to nutrition systems including at least a first and a second reduced calorie infant formula having varying whey to casein protein weight ratios for reducing inflammation-related diseases later in life. Particularly, the nutrition systems may be administered to a newborn infant to reduce the risk of obesity later in life..
Dietary product intended to reduce visceral fat during the pre-operative phase prior to bariatric surgery
An orally administered dietary product intended to reduce an obese person's visceral fat during the pre-operative phase prior to bariatric surgery, the product includes in particular a mixture of: a whey hydrolysate having a molecular weight of between 200 and 10,000 daltons, an isolate and/or a concentrate of whey, and calcium caseinate.. .
Protein seasonings and methods of making the same
A protein seasoning and methods of making the same are provided. A formulation can be provided comprising a base combined with a protein source, which can be combined with various flavored seasonings/ingredients to form protein seasonings that can be added to different foods and/or liquids.
Method for producing a milk product
A method is disclosed for producing an infant formula base, wherein by means of microfiltration, ultrafiltration, and nanofiltration the components of milk are separated into a casein fraction, a whey protein fraction, and a lactose fraction to produce, by suitably combining, a composition in which the amino acid composition is close to that of human milk. An infant formula base having a total protein concentration of about 1.0 to about 1.5% and a β-casein concentration of at least about 11% of the total protein concentration is also disclosed.
Dietary product intended for the prevention of cardiometabolic risk
A dietary product for preventing cardiometabolic risk in humans, in particular for reducing visceral fat and deep subcutaneous fat, includes in particular a mixture of: a whey hydrolysate having a molecular weight of between 200 and 10,000 daltons, an isolate and/or concentrate of whey, and calcium caseinate.. .
Methods for the bioremediation of petroleum in an aquatic environment
In one embodiment, a bioremediation agent and method of bioremediation of an oil spill are disclosed. The bioremediation agent contains oil-digesting bacteria and bacterial nutrients in a buoyant water semi-insoluble and biodegradable casein product.
Reducing the risk of autoimmune disease
The present disclosure provides a method for reducing the risk of autoimmune disease by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition, may reduce the symptoms of autoimmune disease and may be a treatment for autoimmune disease, especially type 1 diabetes.
Crumble process cheese products and methods of production
Crumble process cheese products may be produced by cooling process cheese to freezing temperatures below about 32° f. And holding the process cheese at the freezing temperatures for a sufficient amount of time to cause a freeze-induced denaturation of the protein bonds in the process cheese, thereby providing a modified process cheese with a texture adapted to crumble.
Activating adiponectin by casein hydrolysate
The present disclosure provides a method for activating adiponectin by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce risk of heart attack and help in maintaining healthy weight.
Reducing proinflammatory response
The present disclosure provides a method for suppressing a proinflammatory response by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce the levels of proinflammatory cytokines and may be a treatment for inflammatory disease, especially type 1 diabetes.
The invention relates to a dry compositions for lactic acid bacteria and in particular to a dry composition comprising from 109 to 1013 cfu/g of the composition of lactic acid bacteria cells, wherein the composition is characterized by that it also comprises following amounts of protective agents (all amounts of protective agents below are given relative to 1 g of lactic acid bacteria cells in the composition): from 6 to 9 g of trehalose, from 0.1 to 1 g of inulin and from 0.5 to 3 g of hydrolyzed casein, and by that it does not comprise a salt of alginic acid. The composition has an improved storage stability of the cell of interest.
Continuous cheese production process
Processes and equipment for continuously making a substitute or imitation cheese by feeding a heated first liquid stream including emulsifying salt, water and cheese powder into a cooker which is a twin screw mixer, feeding a heated second liquid stream including oil and casein or a non-dairy protein into the cooker, processing the first liquid stream and the second liquid stream through the cooker to form a cheese composition, and cooling the cheese composition. The cheese composition may be continuously extruded in a desired shape such as sheets or ropes and/or may be continuously cooled and cut into pieces having a reduced size such as a size to approximate shredded cheese..
Dairy based compositions with low lps
The present invention is directed to a method to produce a dairy based food composition with low lps comprising the steps (a) providing a milk with a storage time of less than 264 hours and either (b1) treating the milk with a microfilter of poresize of from 0.01-2 μm such that at least a casein rich fraction and a serum protein rich fraction is obtained, or (b2) treating the milk such that at least 98 wt % of the gram negative bacteria is removed, and heating the milk wherein at least 98wt % of the gram negative bacteria is removed to 60-90° c. The methods of the present invention are very suitable to provide a dairy based food composition wherein less than 5100 eu lps per liter ready to use food composition is present or wherein less than 39 eu lps per gram dry product is present..
Sterilized liquid protein supplement
Disclosed are sterilized liquid protein supplements including extensively hydrolyzed casein for use with human milk and other infant feeding formulas. The sterilized liquid protein supplements have a low ph, thereby inhibiting protein denaturation and reducing microbial growth..
Exogenous opioid peptide-degrading enzyme
The present invention is intended to provide a means for efficiently degrades exogenous opioid peptides. Provided is an exogenous opioid peptide-degrading enzyme preparation which contains one or more components selected from the group consisting of enzyme preparations from penicillium citrinum, aspergillus oryzae, and aspergilius melleus, and exhibits a degradation activity for a wheat gluten-derived opioid peptide and a casein-derived opioid peptide..
A casein hydrolysate formed by controlled hydrolysis of a casein substrate by an aspergillus-derived (fugal) proteolytic preparation is described. The controlled hydrolysis employs a flavorpro-whey™ formulation and a degree of hydrolysis (% dh) of from 5% dh to 15% dh.
Composition containing s-adenosyl-l-methionine with excellent storage stability
The present invention relates to a composition including s-adenosyl-l-methionine; and at least one kind of additive selected from carboxymethylcellulose, hydroxypropylcellulose, soybean polysaccharide, casein sodium, and zein, in which s-adenosyl-l-methionine is extracted from s-adenosyl-l-methionine-containing cells obtained by culturing a microorganism having an ability to produce same, and the content of the additive in the composition falls within the range of 0.05 to 15 times by mass of s-adenosyl-l-methionine in the composition. The present invention provides a composition containing a high concentration of s-adenosyl-l-methionine, which is useful as a water-soluble physiologically active substance, and being excellent in storage stability and bioabsorbability.
Methods for the remediation of algal blooms
In one embodiment, a remediation agent and method of remediation of an algae bloom are disclosed. The remediation agent contains light absorbing compounds in a buoyant water semi-insoluble and biodegradable casein product.
Composition with improved digestibility of proteins
The present invention relates to method to produce a dairy based food composition comprising protein comprising the steps (a) treating the milk such that at least 98% of the pathogens is removed, (b) treating the milk with a microfilter of a poresize of 0.01-2 micron such that at least a casein rich fraction and a serum protein rich fraction is obtained, wherein the milk is subjected to a heating treatment before or after the microfiltration and wherein during the production the milk and products obtained from the milk are not subjected to a heat treatment at a temperature above 90° c., and wherein the serum protein rich fraction and/or the casein rich fraction is processed into a food product. The invention also is directed to products made by the process..
Compositions and methods for augmenting kidney function
A protein-rich nutritional food product composed of a probiotic and an edible isolated protein. The probiotic component may comprise lactobacillus, bacillus, streptococcus bifidobacteria, saccharomyces or leuconostoc.
Enteric delivery of functional ingredients suitable for hot comestible applications
A microencapsulated enteric matrix composition and method for manufacture are provided. The microencapsulated enteric composition includes enteric material, such as sodium caseinate and soy protein, and a functional ingredient contained therein in a core.
Method of producing a composition containing caseino-macropeptide
The present invention pertains to a method of producing caseinomacropeptide (cmp)-containing compositions in high yield and having a very low content of phenylalanine (phe). More specifically, the method involves subjecting a whey derived feed to a combination of ultrafiltration and subsequent cation exchange..
Use of a nucleotide for improving the heat stability of an aqueous micellar casein composition
The invention relates to the use of one or more nucleotides for improving the heat stability of an aqueous micellar casein composition comprising 6 to 20 g per 100 ml of micellar casein, and having a ph of about 6 to 8. The invention also relates to heat-treated liquid nutritional compositions comprising 6 to 20 g, preferably 9-20 g, of protein per 100 ml of the composition and having a ph of about 6 to 8, in which all or a major part of said protein comprises micellar casein, further comprising one or more nucleotides..
Composites containing polypeptides attached to polysaccharides and molecules
This document provides methods and materials related to composites or coatings containing polypeptides attached to polysaccharides and/or molecules. For example, methods and materials related to composites or coatings containing polypeptides (e.g., casein polypeptides) attached to polysaccharides (e.g., cellulose) and/or molecules (e.g., calcium containing molecules such as calcium phosphate and calcium carbonate and/or polyesters such as polylactic acid and polyhydroxybutyrate) are provided.
Aminopyrimidine kinase inhibitors
Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., ck1γ), casein kinase 2 (ck2), pim1, pim2, pim3, the tgfβ pathway, the wnt pathway, the jak/stat pathway, and/or the mtor pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., ck1γ), casein kinase 2 (ck2), pim1, pim2, pim3, the tgfβ pathway, the wnt pathway, the jak/stat pathway, and/or the mtor pathway..
Reduced sodium food products formed of potassium-containing emulsifying salt mixtures and methods of making and using same
A method of preparing a less sodium food product involves forming a reaction mixture of one or more of liquid sodium potassium hydrogen phosphate and liquid sodium dipotassium phosphate and combining a food ingredient with the emulsifying salt mixture. A reduced sodium process cheese product is formed of a sol to gel conversion fat stabilized via a hydrated protein matrix by a combination of potassium caseinate and sodium caseinate in which the caseinates are derived from an emulsifying salt mixture of liquid sodium potassium hydrogen phosphate and liquid sodium dipotassium phosphate, which, prior to reaction, accounts for at least about 2.5 and up to about 8.32 percent by weight of a total weight of the process cheese product.
Method of making a milk protein composition
Described is a method of of providing milk proteins from raw animal milk. The method comprises subjecting the milk to two microfiltration steps.
Method for isolating osteopontin using feeds containing cmp or casein species
The present invention pertains to a method for isolating osteopontin from a milk-derived feed containing caseino macropeptide and/or free beta casein, such as e.g. A feed based on milk serum or sweet whey.
Compositions and methods for improving curd yield of coagulated milk products
Disclosed are compositions and methods for enhancing the yield of coagulated milk products including cheese and other fermented milk products. Admixture of structurally expanded celluloses into milk allows substantial incorporation of additional whey solids and fluids into the caseinate matrix.
Age-tailored nutrition system for infants
The invention relates to the use of a protein source comprising whey and casein proteins for providing an age-tailored nutrition system to an infant which system comprises two infant formulas each appropriate to an infant of a different age and each comprising the protein source wherein the whey casein ratio of each formula is chosen in the range from 100:0 to 40:60 and decreases according to the age of the infant and the protein content of each formula is chosen in the range from 1.5 to 3.0g protein/100 kcal and decreases according to the age of the infant.. .
Age-tailored nutrition system for infants
The invention relates to the use of a protein source comprising whey and casein proteins for providing an age-tailored nutrition system to an infant which system comprises two infant formulas each appropriate to an infant of a different age and each comprising the protein source wherein the whey casein ratio of each formula is chosen in the range from 100:0 to 40:60 and decreases according to the age of the infant and the protein content of each formula is chosen in the range from 1.5 to 3.0 g protein/100 kcal and decreases according to the age of the infant.. .
Methods and compositions of camel derived products
The present invention provides a composition, a dairy product, and a method for treating a disorder in a subject. The composition includes (i) polymeric nanoparticles and (ii) camel derived glycosaminoglycans (gag)s ionic complex encapsulated into the nanoparticles, at least one active ingredient encapsulated into the nanoparticles, or combinations thereof.
Casein kinase 1delta (ck 1delta) inhibitors and their use in the treatment of neurode-generative diseases such as tauopathies
The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (ck1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as alzheimer's disease.. .